EPEMED, the European PErsonalised MEdicine Diagnostics association announces the appointment of its founding board of directors
EPEMED, a membership association formed in August 2009 as a not-for- profit organisation, will provide a platform for harmonisation in the development and implementation of value-based diagnostics across Europe, to make personalised medicine a reality. Personalised Medicine, the use of a person’s clinical, genetic, genomic and environmental information to more precisely and accurately select a medication and its dose for each individual patient, will both improve care and lower costs.
EPEMED has appointed experts in the field of personalised medicine and molecular diagnostics as its founding board of directors:
- Alain Huriez, M.D., Chairman, CEO TcLand Expression
- Mara Aspinall, President & CEO, On-Q-ity, ex. president, Genzyme Genetics
- Vincent Fert, President & CEO Ipsogen
- Werner Kroll, Ph.D., Head Diagnostics Research and Innovation Novartis Molecular Diagnostics
- Iain D. Miller, Ph.D., Senior Director, Oncology Strategy and Theranostics, bioMerieux
- Herman Spolders, BVBA, CEO Oncomethylome Sciences
- Patrick F. Terry, founder Genomic Health & PMC, CEO Technic Solutions
Most read news
Other news from the department people
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.